EDUARDO, Mariana Bustamante, Vlad POPOVICI, Sara IMBODEN, Stefan AEBI, Nadja BALLABIO, Hans Jorg ALTERMATT, Andreas GUNTHERT and Rolf JAGGI. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. BMC Cancer. London: BioMed Central, 2019, vol. 19, June, p. 1-14. ISSN 1471-2407. Available from: https://dx.doi.org/10.1186/s12885-019-5752-8.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases
Authors EDUARDO, Mariana Bustamante (756 Switzerland), Vlad POPOVICI (642 Romania, guarantor, belonging to the institution), Sara IMBODEN (756 Switzerland), Stefan AEBI (756 Switzerland), Nadja BALLABIO (756 Switzerland), Hans Jorg ALTERMATT (756 Switzerland), Andreas GUNTHERT (756 Switzerland) and Rolf JAGGI (756 Switzerland).
Edition BMC Cancer, London, BioMed Central, 2019, 1471-2407.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW Full Text
Impact factor Impact factor: 3.150
RIV identification code RIV/00216224:14310/19:00110435
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1186/s12885-019-5752-8
UT WoS 000470702000003
Keywords in English Breast cancer; Molecular risk scores; Local recurrence; Brain metastasis; PAM50 subtypes; Gene expression measurement; Immunohistochemistry; RNA isolation and processing; Hierarchical clustering
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 24/3/2020 11:29.
Abstract
BackgroundBreast cancer is a leading cause of cancer-related death in women worldwide. Despite extensive studies in all areas of basic, clinical and applied research, accurate prognosis remains elusive, thus leading to overtreatment of many patients. Diagnosis could be improved by introducing multigene molecular scores in standard clinical practice. Several tests that work with formalin-fixed tissue have become routine. Molecular scores usually include several genes representing processes, response to oestrogens, progestogens and human epidermal growth factor receptor 2 (Her2), respectively, which are combined additively in single values. These multi-gene scores have the advantage of being more robust and reproducible than single-gene scores. Their utility may be further enhanced by combining them with classical diagnostic parameters. Here, we present an exploratory study comparing the RISK and research versions of Oncotype DX recurrence score (RS), Prosigna Risk of Recurrence (ROR) and EndoPredict (EP) with respect to their prognostic potential for ipsilateral recurrence and/or distant relapse in brain, and we compared the scores to the intrinsic subtypes based on PAM50.MethodsRNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue cores of primary tumours, local recurrences and brain metastases. Gene expression was measured on a NanoString nCounter Analysis System. Intrinsic subtypes and molecular scores were computed according to published literature and RISK, RS, ROR and EP were compared against each other and to the intrinsic subtypes Luminal A (lumA), Luminal B (lumB), Her2-enriched (Her2), Basal-like (basal), and Normal-like (normal) of PAM50. Local recurrences and brain metastases were compared to their corresponding primary tumours.ResultsAll four molecular scores were highly correlated. Highest correlations were observed among genes related to proliferation while lower correlations were found among oestrogen-related genes. The scores were significantly higher in primary tumours progressing to brain metastases as compared to recurrence-free primary tumours and primary tumours that relapsed as local recurrences.ConclusionsRISK and ROR-P are prognostic for primary tumours metastasizing to the brain. All four scores, RISK, RS, EP and ROR-P failed to discriminate between primary tumours that remained recurrence-free and primary tumours relapsing as local recurrences.
Links
EF16_013/0001761, research and development projectName: RECETOX RI
LM2015051, research and development projectName: Centrum pro výzkum toxických látek v prostředí (Acronym: RECETOX RI)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 21/7/2024 00:17